What is the explanation for diagnosing celiac disease when a patient has positive celiac serology and duodenal biopsy showing Marsh type 2 (crypt hyperplasia with increased intra‑epithelial lymphocytes) or Marsh type 3 (villous atrophy)?

Celiac Disease Diagnosis: Understanding Marsh Type 2 and 3 Histology with Positive Serology

In celiac disease, diagnosis is established when positive celiac serology (anti-tissue transglutaminase IgA, anti-endomysial antibodies, or anti-deamidated gliadin peptides) is combined with duodenal biopsy showing either Marsh type 2 (crypt hyperplasia with increased intraepithelial lymphocytes ≥25/100 enterocytes but preserved villi) or Marsh type 3 (villous atrophy), because this combination confirms both the immune response to gluten and the intestinal damage that defines the disease. 1

Why Both Components Are Required

The diagnostic framework requires two pillars working together:

The Serological Component

• Positive anti-tissue transglutaminase IgA (anti-TG2) demonstrates the systemic immune response to gluten
• Anti-endomysial antibodies (EMA) provide high specificity (99%) for confirming the diagnosis 2
• These antibodies indicate active immune-mediated disease, not just incidental mucosal changes 3

The Histological Component

The Marsh classification captures the progressive spectrum of intestinal damage:

Marsh Type 2 represents an intermediate stage where:

• Intraepithelial lymphocytes are elevated (≥25/100 enterocytes)
• Crypts show hyperplasia (lengthening and increased mitotic activity)
• Villous architecture remains intact
• This pattern, when combined with positive serology, indicates "probable celiac disease" and warrants treatment 1

Marsh Type 3 represents the classic destructive phase with:

• Villous atrophy (flattening of the intestinal surface)
• Crypt hyperplasia
• Increased intraepithelial lymphocytes
• This pattern with positive serology establishes definite celiac disease 1

Why This Dual Approach Matters

Serology Alone Is Insufficient in Adults

While children with anti-TG2 levels >10 times the upper limit of normal plus positive EMA can be diagnosed without biopsy (per ESPGHAN guidelines), adults require histological confirmation because 1:

• Alternative diagnoses causing similar symptoms are more common in adults
• Not all commercial serological assays have equal quality
• Baseline histology is essential for monitoring treatment response and detecting complications like lymphoma
• Villous atrophy has other causes that must be excluded (see differential diagnosis below)

Histology Alone Is Insufficient

Villous atrophy and increased intraepithelial lymphocytes are not specific for celiac disease. The British Society of Gastroenterology guidelines emphasize that numerous conditions mimic celiac histology 1, including:

• Autoimmune enteropathy
• Common variable immunodeficiency
• Medications (olmesartan, NSAIDs, mycophenolate)
• Infections (Giardia, tropical sprue, HIV)
• Crohn's disease
• Small intestinal bacterial overgrowth

Positive serology distinguishes true celiac disease from these mimics 3, 1.

Critical Technical Points

Biopsy Technique

• Obtain at least 4 biopsies: multiple from distal duodenum (D2) and at least one from duodenal bulb (D1) 1, 4
• Combined D1 and D2 sampling increases diagnostic yield because celiac lesions can be patchy 4
• Proper orientation by the laboratory technician is essential for accurate villous-to-crypt ratio assessment 1

The ≥25 IEL Threshold

The threshold of ≥25 intraepithelial lymphocytes per 100 enterocytes is the minimum for abnormality 1. This represents the innate immune response (Marsh I) that precedes structural changes. When combined with crypt hyperplasia (Marsh 2) or villous atrophy (Marsh 3) plus positive serology, it confirms celiac disease.

Common Pitfalls to Avoid

Gluten Avoidance Before Testing

Patients must be consuming gluten when tested 3. If already gluten-free:

• Resume normal diet with 3 slices of wheat bread daily for 1-3 months before repeat testing
• Both serology and histology sensitivity decrease with gluten avoidance

IgA Deficiency

Check total IgA levels 1. In IgA-deficient patients:

• Use IgG-based tests (IgG-TG2, IgG-DGP)
• IgA-TG2 will be falsely negative despite active disease

Equivocal Serology

When serology is weakly positive or equivocal but histology shows Marsh 2 or 3 changes 3:

• Consider HLA-DQ2/DQ8 testing (negative result excludes celiac disease)
• Evaluate response to gluten-free diet
• Consider repeat biopsy if clinical suspicion remains high

Clinical Decision Algorithm

For patients with suspected celiac disease:

1. Check anti-TG2 IgA and total IgA (first-line screening)
2. If anti-TG2 positive → Proceed to endoscopy with ≥4 duodenal biopsies (D1 + D2)
3. Interpret combined results:
   • Positive serology + Marsh 3 = Definite celiac disease → Start gluten-free diet
   • Positive serology + Marsh 2 = Probable celiac disease → Start gluten-free diet, consider HLA testing for confirmation
   • Positive serology + Marsh 0-1 = Consider repeat biopsy, evaluate other causes, assess gluten intake
   • Negative serology + Marsh 2-3 = Not celiac disease → Investigate differential diagnoses 1

The combination of positive serology with Marsh 2 or 3 histology provides the diagnostic certainty needed to commit patients to lifelong gluten-free diet, which is the only current treatment and significantly impacts quality of life, morbidity (preventing malabsorption, osteoporosis, infertility), and mortality (reducing lymphoma risk) 1.